Recent Class Action Lawsuit Filed Against ImmunityBio, Inc. for Securities Fraud

ImmunityBio Faces Class Action Lawsuit

In recent news, ImmunityBio, Inc. (NASDAQ: IBRX) has found itself under legal scrutiny following a class action lawsuit filed by Kessler Topaz Meltzer & Check, LLP. The lawsuit concerns securities fraud allegations and involves investors who acquired shares of ImmunityBio from January 19, 2026, to March 24, 2026.

Overview of the Allegations

According to the complaint, there are significant claims that ImmunityBio provided false and misleading information about its lead biologic product, Anktiva. The key allegations highlight that the company's Executive Chairman, Patrick Soon-Shiong, made exaggerated assertions regarding Anktiva’s capabilities on a podcast, stating that it could cure and prevent all forms of cancer. The FDA subsequently issued a warning letter citing these inaccuracies, which arguably impacted the investors' financial situations.

The allegations specify that the statements made violated regulations set forth in the Federal Food, Drug, and Cosmetic Act, as they constituted material misstatements and omissions about the company’s business and prospects. These misleading claims have left investors questioning the integrity of the company’s public image and fundamentals.

The Impact on Investors

As a direct result of these allegations and the subsequent FDA declaration, ImmunityBio's stock suffered a notable decline. On March 24, 2026, there was a steep drop of $1.98 per share, equating to a 21.12% decrease, dropping the share price to $7.42 per share, affecting many investors who had trusted the company’s prior assurances. The lawsuit represents those who feel they were misled and suffered financial losses due to these disingenuous statements.

What Investors Can Do

The law firm encourages impacted investors to act swiftly. Affected parties have until May 26, 2026, to file for lead plaintiff status—a process that will enable them to represent the interests of the class in pursuing recovery of losses. To find out more information or to discuss potential legal options with Kessler Topaz Meltzer & Check, interested investors may contact attorney Jonathan Naji via phone or email. Notably, consultations with the firm hold no obligation and are free of charge, thus presenting a risk-free opportunity for investors to explore their legal rights.

Conclusion

As this legal battle unfolds, the saga of ImmunityBio serves as a crucial reminder for investors to remain vigilant regarding the claims and operations of companies they invest in. With Kessler Topaz leading the charge for accountability during this turbulent time, shareholders are encouraged to stay informed and explore avenues for recovery. This class action presents an opportunity for voiced grievances against any potential wrongdoing in the management's disclosures. As of now, ImmunityBio's journey remains a focal point in the realm of investor protection and compliance with securities regulations.